Personally found it brilliant how the authors designed this study and all the hard work behind it.
As this phase 2 study approaches patients already treated with statins (low and high dose) with or without ezetimibe and most of them on PCSK9 inhibitors (160/160 in SC group and 102/106 in IV group). Given Evinacumab's effectiveness, is it early to start to consider this agent as a promising third line just after statins and PCSK9 inhibitors? I would like to know your thoughts about including evinacumab before ezetimibe, niacin, or Mipomersen in the treatment for hyperlipidemia.
-
Like
Easy one-click social registration
Is this safe?We only receive the minimum information necessary to verify your account. We never get access to your friends/contacts or your profile, and we never post on your behalf. Your social account is used for logging in only.
ORWhy we require registering to vote
In order to ensure a fair voting process and to make sure that no one votes more than once, we ask that you register either with a social networking account (easiest, only requires one click) or by registering with your email address (this will require you to click on a verification email that we will send you).
You only need to register once.
- 1
Log in or create an account to comment
Social Login
Email Login
Log in via Email
Back to Social Login
Create Your Account